Table 2.
Comparison of protein levels in monocytes of lithium completed responders and non-responders between before and after lithium treatment.
| Completed-Responders | Completed-Non-Responders | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Analytes | Before Lithium | After Lithium | Before vs. After Lithium | Before Lithium | After Lithium | Before vs. After Lithium | ||||
| n | Mean ± SD | n | Mean ± SD | p-Value | n | Mean ± SD | n | Mean ± SD | p-Value | |
| BAK | 9 | 23.2 ± 5.0 | 9 | 26.5 ± 3.2 | 0.118 | 4 | 20.5 ± 2.6 | 4 | 19.6 ± 6.8 | 0.826 |
| BCL-2 | 8 | 22.1 ± 5.0 | 8 | 22.8 ± 2.8 | 0.742 | 4 | 22.9 ± 5.4 | 4 | 13.0 ± 9.7 | 0.124 |
| BCL-2 A1 | 9 | 1.4 ± 0.3 | 9 | 1.5 ± 0.1 | 0.474 | 4 | 1.5 ± 0.2 | 4 | 1.4 ± 0.2 | 0.526 |
| BDNF | 9 | 50.1 ± 13.3 | 9 | 56.1 ± 9.2 | 0.277 | 3 | 44.3 ± 6.2 | 3 | 36.2 ± 16.3 | 0.461 |
| Calmodulin | 9 | 48.4 ± 12.8 | 9 | 52.2 ± 9.2 | 0.474 | 4 | 41.6 ± 10.6 | 4 | 41.6 ± 20.2 | 0.999 |
| Fyn | 9 | 34.4 ± 8.5 | 9 | 40.4 ± 4.1 | 0.074 | 4 | 35.3 ± 7.3 | 4 | 24.3 ± 8.9 | 0.106 |
| GSK3 β | 9 | 29.8 ± 10.3 | 9 | 36.6 ± 5.8 | 0.103 | 4 | 29.4 ± 7.6 | 4 | 24.8 ± 6.7 | 0.393 |
| HMGB1 | 8 | 25.8 ± 9.6 | 8 | 27.0 ± 10.5 | 0.806 | 4 | 18.1 ± 3.2 | 4 | 16.4 ± 7.1 | 0.689 |
| iNOS | 9 | 26.5 ± 13.8 | 9 | 29.3 ± 6.9 | 0.598 | 4 | 24.0 ± 5.8 | 4 | 17.2 ± 6.4 | 0.164 |
| IRS2 | 9 | 43.7 ± 14.0 | 9 | 44.7 ± 11.4 | 0.860 | 4 | 45.7 ± 7.9 | 4 | 38.7 ± 16.0 | 0.456 |
| MARCKS | 9 | 37.9 ± 9.9 | 9 | 43.1 ± 6.9 | 0.210 | 4 | 27.9 ± 10.2 | 4 | 20.2 ± 9.0 | 0.300 |
| mTor | 9 | 23.0 ± 11.5 | 9 | 22.1 ± 4.7 | 0.821 | 4 | 37.1 ± 11.6 | 4 | 35.4 ± 18.6 | 0.885 |
| NLRP3 | 9 | 33.5 ± 11.0 | 9 | 39.7 ± 6.9 | 0.172 | 3 | 35.1 ± 7.9 | 3 | 23.6 ± 12.0 | 0.236 |
| NR3C1 | 8 | 7.0 ± 1.5 | 8 | 8.6 ± 1.2 | 0.029 | 4 | 8.4 ± 2.6 | 4 | 4.6 ± 1.2 | 0.037 |
| PDEB4 | 9 | 20.7 ± 6.4 | 9 | 26.5 ± 3.2 | 0.027 | 3 | 30.8 ± 9.4 | 3 | 21.1 ± 6.9 | 0.223 |
| PGM1 | 9 | 41.5 ± 11.2 | 9 | 46.2 ± 7.1 | 0.303 | 4 | 39.8 ± 7.8 | 4 | 34.7 ± 12.8 | 0.518 |
| phospho-CREB | 9 | 46.3 ± 9.7 | 9 | 52.8 ± 5.6 | 0.101 | 4 | 46.8 ± 6.9 | 4 | 40.3 ± 17.9 | 0.524 |
| phospho-Fyn/Yes | 9 | 24.7 ± 10.5 | 9 | 27.6 ± 7.7 | 0.519 | 4 | 26.5 ± 5.6 | 4 | 18.8 ± 5.2 | 0.089 |
| phospho-GSK3 β | 9 | 4.5 ± 1.4 | 9 | 6.6 ± 2.8 | 0.073 | 4 | 5.1 ± 1.2 | 4 | 7.2 ± 5.3 | 0.458 |
| phospho-GSK3 αβ | 9 | 3.1 ± 1.1 | 9 | 3.2 ± 1.1 | 0.987 | 4 | 4.4 ± 1.2 | 4 | 3.6 ± 1.1 | 0.373 |
| phospho-NFkB-P65 | 9 | 9.7 ± 5.4 | 9 | 10.9 ± 2.8 | 0.590 | 4 | 8.7 ± 3.2 | 4 | 7.5 ± 1.4 | 0.510 |
| PKA C- α | 9 | 42.3 ± 10.9 | 9 | 47.9 ± 7.1 | 0.213 | 4 | 38.8 ± 3.2 | 4 | 29.1 ± 13.7 | 0.296 |
| PKC- θ | 9 | 5.2 ± 2.0 | 9 | 4.4 ± 1.0 | 0.322 | 4 | 6.0 ± 3.0 | 4 | 3.7 ± 1.9 | 0.229 |
| PPAR- γ | 9 | 40.3 ± 11.5 | 9 | 46.4 ± 7.4 | 0.206 | 4 | 39.9 ± 9.0 | 4 | 32.4 ± 12.3 | 0.364 |
| Timeless | 9 | 1.8 ± 0.5 | 9 | 1.8 ± 0.3 | 0.887 | 4 | 1.8 ± 0.1 | 4 | 1.4 ± 0.5 | 0.253 |
| TNFAIP3 | 9 | 22.8 ± 9.6 | 9 | 24.5 ± 6.5 | 0.659 | 4 | 19.5 ± 2.8 | 4 | 14.8 ± 4.5 | 0.128 |
| TPH1 | 9 | 16.1 ± 5.9 | 9 | 19.1 ± 4.2 | 0.230 | 4 | 16.1 ± 4.4 | 4 | 12.2 ± 3.9 | 0.240 |
| XBP1 | 9 | 1.3 ± 0.3 | 9 | 1.3 ± 0.2 | 0.572 | 4 | 1.6 ± 0.7 | 4 | 1.2 ± 0.2 | 0.218 |
Abbreviation: BAK: BAX, BCL2-Associated × Protein; BCL-2: B-cell lymphoma 2; BCL-2 A1: Bcl-2-related protein A1; BDNF: brain-derived neurotrophic factor; Calmodulin: calcium-modulated protein; Fyn: a tyrosine kinase belongs to the Src family of tyrosine kinases including src, fyn, and yes; GSK3β: glycogen synthase kinase 3 beta; HMGB1: High mobility group box 1 protein; iNOS: inducible isoform nitric oxide synthases; IRS2: Insulin receptor substrate 2; MARCKS: myristoylated alanine-rich C-kinase substrate; mTor: mammalian target of rapamycin; NLRP3: NACHT, LRR and PYD domains-containing protein 3; NR3C1: nuclear receptor subfamily 3, group C, member 1; phospho-CREB: phosphorylated cAMP response element-binding protein (Ser133); phospho-Fyn/Yes: phosphorylated Fyn(Y530)/Yes(Y537); phospho-GSK3αβ: phosphorylated glycogen synthase kinase 3 alpha(Tyr279) beta(Tyr216); phospho-GSK3β: phospho-glycogen synthase kinase 3 beta(Tyr216); phospho-NFkB-P65: phosphorylated nuclear factor NF-kappa-B p65(Ser536) subunit; PDEB4: cAMP-specific 3′,5′-cyclic phosphodiesterase 4B; PGM1: phosphoglucomutase 1; PKA C-α: protein kinase A catalytic subunit; PKC- θ: protein kinase C theta; PPAR-γ: peroxisome proliferator-activated receptor gamma; Timeless: a protein is necessary of proper functioning of circadian rhythm; TNFAIP3: tumor necrosis factor, alpha-induced protein 3; TPH1: tryptophan hydroxylase 1; XBP1: X-box binding protein 1.